Wall Street analysts expect Scpharmaceuticals Inc (NASDAQ:SCPH) to announce ($0.58) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Scpharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.57). The company is scheduled to report its next earnings report on Monday, August 13th.
According to Zacks, analysts expect that Scpharmaceuticals will report full year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.35) to ($2.09). For the next financial year, analysts expect that the firm will report earnings of ($2.40) per share, with EPS estimates ranging from ($2.48) to ($2.31). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Scpharmaceuticals.
SCPH has been the subject of a number of analyst reports. ValuEngine raised Scpharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research cut Scpharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 11th. Jefferies Financial Group cut their price objective on Scpharmaceuticals from $26.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, June 14th. BMO Capital Markets cut their price objective on Scpharmaceuticals from $24.00 to $14.00 and set an “outperform” rating for the company in a report on Thursday, June 14th. Finally, Leerink Swann lowered their target price on Scpharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research note on Thursday, June 14th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $12.67.
Several large investors have recently made changes to their positions in SCPH. BlackRock Inc. increased its stake in shares of Scpharmaceuticals by 21,048.8% in the first quarter. BlackRock Inc. now owns 288,469 shares of the company’s stock valued at $3,577,000 after buying an additional 287,105 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in Scpharmaceuticals in the fourth quarter worth about $653,000. Northern Trust Corp acquired a new stake in Scpharmaceuticals in the first quarter worth about $595,000. Citigroup Inc. acquired a new stake in Scpharmaceuticals in the first quarter worth about $481,000. Finally, Millennium Management LLC acquired a new stake in Scpharmaceuticals in the fourth quarter worth about $462,000. Institutional investors own 44.74% of the company’s stock.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
See Also: What is the NASDAQ Stock Market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.